Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 2/20 | 0.65 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.65 |
| ▸ | PLOD2 | O00469 | 2/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.53 |
| ▸ | APP | P05067 | 1/20 | 0.53 |
| ▸ | GAA | P10253 | 1/20 | 0.53 |
| ▸ | HCAR3 | P49019 | 1/20 | 0.53 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.53 |
| ▸ | THRB | P10828 | 1/20 | 0.53 |
| ▸ | PLOD3 | O60568 | 1/20 | 0.53 |
| ▸ | PLOD1 | Q02809 | 1/20 | 0.53 |
| ▸ | F7 | P08709 | 1/20 | 0.52 |
| ▸ | F3 | P13726 | 1/20 | 0.52 |
| ▸ | SARM1 | Q6SZW1 | 1/20 | 0.52 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.52 |
| ▸ | SIRT6 | Q8N6T7 | 1/20 | 0.52 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.52 |
| ▸ | SIRT3 | Q9NTG7 | 1/20 | 0.52 |
| ▸ | SIRT5 | Q9NXA8 | 1/20 | 0.52 |
| ▸ | SIRT4 | Q9Y6E7 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30096366 | 1.00 | HDAC1 (0.65) | HDAC1HDAC8PLOD2ALDH1A1APP | |
| SCHEMBL8545882 | 0.95 | HDAC1 (0.68) | HDAC1HDAC8PLOD2ALDH1A1APP | |
| SCHEMBL9549825 | 0.93 | HDAC1 (0.70) | HDAC1HDAC8PLOD2ALDH1A1APP | |
| SCHEMBL9405126 | 0.89 | PLOD2 (0.62) | HDAC1HDAC8PLOD2ALDH1A1APP | |
| SCHEMBL4947413 | 0.87 | PLOD2 (0.61) | HDAC1HDAC8PLOD2ALDH1A1APP | |
| SCHEMBL7075878 | 0.87 | PLOD2 (0.69) | HDAC1HDAC8PLOD2ALDH1A1APP | |
| SCHEMBL13518550 | 0.84 | HDAC1 (0.56) | HDAC1HDAC8PLOD2ALDH1A1APP | |
| SCHEMBL8572804 | 0.84 | HDAC1 (0.63) | HDAC1HDAC8PLOD2ALDH1A1APP | |
| SCHEMBL552456 | 0.84 | HDAC1 (0.63) | HDAC1HDAC8PLOD2ALDH1A1APP | |
| SCHEMBL17700981 | 0.84 | HDAC1 (0.63) | HDAC1HDAC8PLOD2ALDH1A1APP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 67 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4597111-A1 | USE OF METABOLIC MARKER FOR DIAGNOSIS OF LUNG CANCER STAGING AND KIT | Harbin Metanotitia Inc. (CN) | 2025-08-06 | — | — | EP | claimed |
| CN-117388495-B | Application of metabolic marker for diagnosing lung cancer stage and kit | 哈尔滨脉图精准技术有限公司 | 2024-02-09 | — | — | CN | claimed |
| US-11884644-B1 | Method for synthesizing (S)-nicotine and intermediate thereof | SHANDONG JINCHENG PHARMACEUTICAL CHEMICAL CO., LTD. (CN) | 2024-01-30 | — | — | US | claimed |
| CN-117388495-A | Application of metabolic marker for diagnosing lung cancer stage and kit | 哈尔滨脉图精准技术有限公司 | 2024-01-12 | — | — | CN | claimed |
| CN-116148392-A | Biomarker for diagnosing metabolic-related fatty liver disease, kit and application thereof | 北京大学 | 2023-05-23 | — | — | CN | claimed |
| CN-115820762-B | Process for the synthesis of (S) -nicotine and intermediates thereof | 山东金城医药化工有限公司 | 2023-05-16 | — | — | CN | claimed |
| CN-115627282-B | Synthesis of (S) -nicotine and intermediates thereof | 山东金城医药化工有限公司 | 2023-04-11 | — | — | CN | claimed |
| CN-115820762-A | Process for the synthesis of (S) -nicotine and intermediates thereof | 山东金城医药化工有限公司 | 2023-03-21 | — | — | CN | claimed |
| CN-115627282-A | Synthesis of (S) -nicotine and intermediates thereof | 山东金城医药化工有限公司 | 2023-01-20 | — | — | CN | claimed |
| EP-4597111-A1 | USE OF METABOLIC MARKER FOR DIAGNOSIS OF LUNG CANCER STAGING AND KIT | Harbin Metanotitia Inc. (CN) | 2025-08-06 | — | — | EP | disclosed |
| CN-115404249-B | Preparation method and application of (S) -nicotine intermediate | 重庆博腾制药科技股份有限公司 | 2024-07-05 | — | — | CN | disclosed |
| CN-117388495-B | Application of metabolic marker for diagnosing lung cancer stage and kit | 哈尔滨脉图精准技术有限公司 | 2024-02-09 | — | — | CN | disclosed |
| CN-117388495-B | Application of metabolic marker for diagnosing lung cancer stage and kit | 哈尔滨脉图精准技术有限公司 | 2024-02-09 | — | — | CN | disclosed |
| US-11884644-B1 | Method for synthesizing (S)-nicotine and intermediate thereof | SHANDONG JINCHENG PHARMACEUTICAL CHEMICAL CO., LTD. (CN) | 2024-01-30 | — | — | US | disclosed |
| EP-0234729-B1 | QUINONE DERIVATIVES, THEIR PRODUCTION AND USE | Takeda Chemical Industries, Ltd. (JP) | 1991-12-27 | — | — | EP | disclosed |
| US-4985447-A | USEFUL FOR TREATMENT AND PREVENTION OF DISEASES DUE TO DYSFUNCTION OF HEART, BRAIN, LUNG AND KIDNEY | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1991-01-15 | — | — | US | disclosed |
| US-4889941-A | Synthetic flavonoids as inhibitors of leukotrienes and 5-lipoxygenase | FISONS CORPORATION (US) | 1989-12-26 | — | — | US | disclosed |
| US-4851413-A | TREATMENT OF HEART, BRAIN, LUNG OR KIDNEY DISORDERS | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1989-07-25 | — | — | US | disclosed |
| EP-0288077-A2 | Synthetic flavonoids as inhibitors of leukotrienes and 5-lipoxygenase | PENNWALT CORPORATION (US) | 1988-10-26 | — | — | EP | disclosed |
| EP-0234729-A2 | Quinone derivatives, their production and use | Takeda Chemical Industries, Ltd. (JP) | 1987-09-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11884644-B1 | Method for synthesizing (S)-nicotine and intermediate thereof | BHMT, NNMT, CYP2S1 | HDAC1 1026/4885HDAC8 2927/4885PLOD2 1944/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.